CLOVIS ONCOLOGY Forum: Community User: Maroni

Clovis Oncology Inc. (NASDAQ:CLVS) will post its Q216 quarterly earnings results on Monday, August 8th. Analysts expect Clovis Oncology to post earnings of ($2.13) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.39) by $0.22. During the same quarter last year, the business earned ($1.86) earnings per share. The company’s revenue was up NaN% on a year-over-year basis. On average, analysts expect Clovis Oncology to post $-8.00 EPS for the current fiscal year and $-4.85 EPS for the next fiscal year. Shares of Clovis Oncology Inc. (NASDAQ:CLVS) opened at 15.23 on Thursday. The firm’s market capitalization is $584.60 million. The firm has a 50-day moving average of $14.09 and a 200 day moving average of $16.52. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $116.75. A number of equities research analysts have recently commented on CLVS shares. Mizuho reduced their price objective on shares of Clovis Oncology from $21.00 to $15.00 and set a “neutral” rating on the stock in a research note on Monday, April 11th. Piper Jaffray Cos. reissued a “neutral” rating and set a $18.00 target price on shares of Clovis Oncology in a research note on Tuesday, April 12th. Zacks Investment Research lowered shares of Clovis Oncology from a “hold” rating to a “sell” rating in a research note on Tuesday, April 12th. Stifel Nicolaus reissued a “buy” rating and set a $30.00 target price on shares of Clovis Oncology in a research note on Tuesday, April 12th. Finally, JPMorgan Chase & Co. lowered shares of Clovis Oncology from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $42.00 to $15.00 in a research note on Wednesday, April 13th. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $29.25. Clovis Oncology, Inc (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer.

sieht auf jeden FALL so aus

Chart. ..Ausbruch oder wie soll ich das verstehen?

https://t.co/NqjTkmASkQ

mal sehen wo die Richtung zum 8.8 hingeht...

Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8 , after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.

KOLs discuss #PARP inhibitor #rucaparib after $CLVS rejigs #LOH cutoff for #non-BRCA ovarian cancer patients

Nein machst du nicht. .hab kurz überflogen aber zZ gaaaanz gaaaanz wenig Zeit gehabt.Ab nächste WOCHE wirds ruhiger!!!Grüsse

Sieht so aus :) Und Infos verbreiten für investierte bzw interessierte Aktionäre

Vanhalen, redest du mit dir selbst?

In diversen Foren wird über ein Buy-Out spekuliert ..... Hmm

Bleibt die Frage, warum er jetzt über 5% hält, und seit wann?

Morgan Stanley owns 1,697,692 shares or 5.2%: 13G filed by Morgan Stanleyhttps://t.co/FDMoNz1mt3,https://t.co/uXklE7bINS

Schlechter Tag.....

@ACInvestorBlog $CLVS CMF is now positive.....buying momentum is starting to rise, a breakout could be possible.https://t.co/JwxWQSVgUO

Kazazian Asset Management LLC purchased a new stake in Clovis Oncology Inc. (NASDAQ:CLVS) during the first quarter, Holdings Channel reports. The fund purchased 14,666 shares of the biopharmaceutical company’s stock, valued at approximately $282,000. Clovis Oncology comprises 0.5% of Kazazian Asset Management LLC’s portfolio, making the stock its 24th largest position. Several other hedge funds have also recently modified their holdings of the company. State Street Corp boosted its stake in shares of Clovis Oncology by 21.2% in the first quarter. State Street Corp now owns 1,797,874 shares of the biopharmaceutical company’s stock valued at $34,525,000 after buying an additional 313,893 shares during the last quarter. Redmile Group LLC boosted its stake in shares of Clovis Oncology by 87.5% in the fourth quarter. Redmile Group LLC now owns 1,795,936 shares of the biopharmaceutical company’s stock valued at $62,858,000 after buying an additional 838,302 shares during the last quarter. HealthCor Management L.P. purchased a new stake in shares of Clovis Oncology during the fourth quarter valued at approximately $53,375,000. BlackRock Institutional Trust Company N.A. boosted its stake in shares of Clovis Oncology by 7.1% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 825,085 shares of the biopharmaceutical company’s stock valued at $15,842,000 after buying an additional 54,476 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of Clovis Oncology during the first quarter valued at approximately $9,896,000. Shares of Clovis Oncology Inc. (NASDAQ:CLVS) traded down 0.07% during midday trading on Monday, hitting $14.72. The stock had a trading volume of 66,652 shares. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $116.75. The stock has a 50-day moving average of $14.76 and a 200 day moving average of $18.53. The stock’s market cap is $565.03 million.